Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 USD | +0.96% | +3.45% | -49.80% |
30/05 | Baird Starts agilon health With Neutral Rating, $6 Price Target | MT |
24/05 | Truist Lifts Price Target on agilon health to $6.50 From $6.40, Maintains Hold Rating | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The stock, which is currently worth 2024 to 0.39 times its sales, is clearly overvalued in comparison with peers.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company appears highly valued given the size of its balance sheet.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-49.80% | 259.09Cr | C- | ||
-23.90% | 281.48Cr | - | ||
-22.24% | 262.55Cr | C+ | ||
+1.34% | 22Cr | - | ||
-45.28% | 18Cr | - | - | |
-32.40% | 12Cr | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AGL Stock
- Ratings agilon health, inc.